Replies to post #76517 on Biotech Values

[iwfal]

ZGEN rib/ifn data - The ifn/rib combo data is actually, and somewhat surprisingly, not particularly good compared to the monotherapy data. More AE and equivalent or less efficacy than the monotherapy. At the very least it is likely to make the ph ii trial more complicated because they may want to continue a monotherapy arm in the ph ii.

Also, given the comparatively high rate of SAE in the 1.5 weekly combo arm it is possible that they question going to 3.0 weekly combo. It would be nice to know what they plan on doing inre that possible dose. And kudos to Tony who was worried that going down a dose indicated a problem at the 1.5 combo dosing. There is the appearance of such a problem.

[grandpatb]

When Wyeth rec'd FDA approval for Premarin (conjugated estrogens)Vaginal Cream it came with a boxed warning "Endometrial Cancer, Cardiovascular Disorders & Probable Dementia for Estrogen-Alone Therapy." & "Cardiovascular Disorder, Breast Cancer & Probable Dementia for for Estrgen Plus Progestin Therapy."
I'd say Zygen is looking good(in combo with Rib.) & it's still cheap as dirt. hint hint.